Specialty Biopharma
- Pipeline
- Biologics
- Biosimilars
XTMAB-16
An Investigational New Drug (IND) candidate developed by Xentria to suppress the physiologic response to tumor necrosis factor.
Sarcoidosis - A rare inflammatory disease that interferes with an organ’s structure and function.
Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organ of the body.
- Lungs are involved in approximately 90% of cases.
- Almost any organ can be affected by this rare disease.
- When left untreated, inflammation can lead to fibrosis which is permanent scarring of the organ tissue.
- Typically, spontaneous disease resolution can occur within 12-36 months of symptom onset.
- Severe cases of progressive disease can become advanced and chronic in approximately 25% of cases.
- Organ inflammation or fibrosis can cause many physical and psychological symptoms of the body.
What We Know
- Sarcoidosis is a rare inflammatory disease that interferes with an organ’s structure and function.
- Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organ of the body.
- The exact cause of sarcoidosis is unknown; researchers continue to explore genetic, seasonal and occupational influences.
Symptoms
90%
of cases the lungsare involved.
25%
of patients haveeye symptoms.
25%
of patients developa skin symptom.
5%
of patients haveheart-related
symptoms.
Treatment
- Many people experience mild symptoms and do not require treatment at any time. Treatment for this disease is often started to resolve symptoms or prevent disease progression.
- Current guidelines also recommend treatments that may help improve health-related quality of life. If you do require treatment, it is important to work with your medical doctor to explore the treatment decision that works best for you.
You might also be interested
The brands mentioned here are the trademarks of their respective owners.